Journal Watch · Journal of Controlled Release · 2026

Multiaspect layered double hydroxide nanohybrid counteracts pathophysiological cascade for ischemic stroke intervention.

This multi-targeted nanosheet offers spatiotemporally controlled therapy for IS, addressing its complex pathogenesis.

Dong Y, Su Y, Sun G et al.Journal of Controlled Release3 min readPharma relevance 75/100

DOI: 10.1016/j.jconrel.2026.114737PMID: 41724243Study type: preclinical (animal / model) study

TL;DR

This multi-targeted nanosheet offers spatiotemporally controlled therapy for IS, addressing its complex pathogenesis.

Key findings

  • In a mouse model of transient ischemia, S-E@LDH reduces neuronal damage, neuroinflammation and cerebral edema, improving motor function.
  • This multi-targeted nanosheet offers spatiotemporally controlled therapy for IS, addressing its complex pathogenesis.

What they did

In the acute phase, cellular damage is reduced by effectively chelating Ca<sup>2+</sup>, scavenging reactive oxygen/nitrogen and disrupting the Ca<sup>2+</sup>-ROS amplification loop. Importantly, SAA stabilized in the LDH matrix undergoes spatiotemporally controlled release relying on the acidic pH of the post-ischemic environment, and targeted, precise administration reprograms microglia to an M2 phenotype, helping to restore brain homeostasis.

Full abstract (original)

Background: Ischemic stroke (IS) therapy remains challenging due to dynamic ischemia-reperfusion pathology. Here, we propose a hybrid nanosheet platform (S-E@LDH) consisting of a layered double hydroxide (LDH) matrix MgAlRu with broad-spectrum enzyme mimetic activity, with the addition of the calcium chelator ethylene glycol tetraacetic acid (EGTA) and the anti-inflammatory agent salvianic acid A (SAA), which rationally integrates the "calcium dysregulation-oxidative stress-inflammation" triple synergistic regulation mode.

What they did: In the acute phase, cellular damage is reduced by effectively chelating Ca<sup>2+</sup>, scavenging reactive oxygen/nitrogen and disrupting the Ca<sup>2+</sup>-ROS amplification loop. Importantly, SAA stabilized in the LDH matrix undergoes spatiotemporally controlled release relying on the acidic pH of the post-ischemic environment, and targeted, precise administration reprograms microglia to an M2 phenotype, helping to restore brain homeostasis.

Results & conclusions: In a mouse model of transient ischemia, S-E@LDH reduces neuronal damage, neuroinflammation and cerebral edema, improving motor function. This multi-targeted nanosheet offers spatiotemporally controlled therapy for IS, addressing its complex pathogenesis.

Abstract © the authors / Journal of Controlled Release (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jconrel.2026.114737 · PubMed 41724243.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Journal of Controlled Release for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Controlled Release study find?

This multi-targeted nanosheet offers spatiotemporally controlled therapy for IS, addressing its complex pathogenesis.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal of Controlled Release in 2026. In the acute phase, cellular damage is reduced by effectively chelating Ca<sup>2+</sup>, scavenging reactive oxygen/nitrogen and disrupting the Ca<sup>2+</sup>-ROS amplification loop.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.jconrel.2026.114737. PubMed ID: 41724243. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Dong Y, Su Y, Sun G et al.. Multiaspect layered double hydroxide nanohybrid counteracts pathophysiological cascade for ischemic stroke intervention.. Journal of Controlled Release (2026). DOI: 10.1016/j.jconrel.2026.114737.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/multiaspect-layered-double-hydroxide-nanohybrid-counteracts-pathophysiol-114737/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides